Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study

Sandro Barni, Luca Livraghi, Maria Morritti, Patrizia Vici, Andrea Michelotti, Saverio Cinieri, Caterina Fontanella, Luca Porcu, Lucia Del Mastro, Fabio Puglisi

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

Original languageEnglish
Pages (from-to)33-44
Number of pages12
JournalFuture Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • database
  • eribulin mesylate
  • metastatic breast cancer
  • real-world
  • safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study'. Together they form a unique fingerprint.

Cite this